North America to Stay Exponentially Tuned in the Anti Obesity Prescription Market between 2020 and 2030

Globally, obesity is a public health problem. Obesity is a genetic and chronic metabolic disease involving accumulation of excessive or abnormal fat in the body. It contributes to risk of chronic conditions such as cancer, hypertension, cardiovascular diseases, diabetics, obstructive sleep apnea, ventilatory failure, renal failure and asthma. According to a World Health Organization (WHO) report published in 2014, around 3.4 million adults in the world die each year due to obesity related issues. Increasing prevalence of obesity among children and adults is posing a threat and developing nations. Effective intervention strategies such as increased physical activity, behavioral and dietary changes are commonly used to control and prevent obesity. Obesity has a major impact on population longevity and health related expense.

To remain ‘ahead’ of your competitors, request for a sample here@ https://www.persistencemarketresearch.com/samples/3381

North America dominates the global market for anti-obesity prescription due to increasing prevalence of obesity and lifestyle associated diseases. Asia followed by the Europe are expected to show high growth rates in the next five years in the global anti-obesity prescription market. China and India are expected to be the fastest growing anti-obesity prescription markets in Asia-Pacific region. Some of the key driving forces for anti-obesity prescription market in emerging countries are large pool of patients, increased government funding and improving healthcare infrastructure.

In recent times there is increased use of anti-obesity prescription due to increasing obesity endemic. Sedentary lifestyle and junk food habits, increasing healthcare expenditure and rise in aging population are some of the key factors driving the growth for global anti-obesity prescription market. In addition, increasing healthcare awareness is also fuelling the growth of the global anti-obesity prescription market. However, side effects of anti-obesity drugs, high drug development cost and strict regulatory framework are some of the major factors restraining the growth for the global anti-obesity prescription market.

New researches for discovery of novel drugs for treatment of obesity would develop opportunity for the global anti-obesity prescription market. However, unfavorable reimbursements policies could lead a challenge for the global anti-obesity prescription market.

To receive extensive list of important regions, ask for TOC here @ https://www.persistencemarketresearch.com/toc/3381

Some of the major companies operating in the global anti-obesity prescription market are ,

7TM Pharma
zydus Cadila
Akrimax Pharmaceuticals
Zealand Pharma
Arrowhead Research
Arena Pharmaceuticals, Inc
Compellis Pharmaceuticals
Yungjin Pharm
Alpex Pharma SA
Bridge BioResearch
Key points covered in the report

Report segments the market on the basis of types, application, products, technology, etc (as applicable)
The report covers geographic segmentation
North America
Europe
Asia
RoW
The report provides the market size and forecast for the different segments and geographies for the period of 2010 to 2020
The report provides company profiles of some of the leading companies operating in the market
The report also provides porters five forces analysis of the market.
For in-depth competitive analysis, Check Pre-Book here @ https://www.persistencemarketresearch.com/checkout/3381

Contact Us:
305 Broadway
7th Floor
New York City, NY 10007
United States
U.S.A - Canada Toll-Free: 800-961-0353
Email: sales@persistencemarketresearch.com

Persistence Market Research (PMR) is an innovative and specialized publisher of market intelligence reports and consulting services. Prompt delivery, in-depth research, and high quality are the sacrosanct principles of PersistenceMarketResearch.

This release was published on openPR.